Literature DB >> 29966171

Risk factors for pleural effusion recurrence in patients with malignancy.

Horiana B Grosu1, Sofia Molina1,2, Roberto Casal3, Juhee Song4, Liang Li4, Javier Diaz-Mendoza5, Chakravarthy Reddy6, Lonny Yarmus7, Dante Schiavo8, Michael Simoff5, Jared Johnstun6, Abu-Awwad Raid3, David Feller-Kopman7, Hans Lee7, Sarina Sahetya7, Finbar Foley8, Fabien Maldonado9, Xin Tian1, Laila Noor1, Russell Miller1, Lakshmi Mudambi1, Timothy Saettele1, Macarena Vial-Rodriguez1, Gerogie A Eapen1, David E Ost1.   

Abstract

BACKGROUND AND
OBJECTIVE: The main purpose of treatment in patients with malignant pleural effusion (MPE) is symptom palliation. Currently, patients undergo repeat thoracenteses prior to receiving a definitive procedure as clinicians are not aware of the risk factors associated with fluid recurrence. The primary objective of this study was to identify risk factors associated with recurrent symptomatic MPE.
METHODS: Retrospective multicentre cohort study of patients who underwent first thoracentesis was performed. The primary outcome was time to fluid recurrence requiring intervention in patients with evidence of metastatic disease. We used a cause-specific hazard model to identify risk factors associated with fluid recurrence. We also developed a predictive model, utilizing Fine-Gray subdistribution hazard model, and externally validated the model.
RESULTS: A total of 988 patients with diagnosed metastatic disease were included. Cumulative incidence of recurrence was high with 30% of patients recurring by day 15. On multivariate analysis, size of the effusion on chest X-ray (up to the top of the cardiac silhouette (hazard ratio (HR): 1.84, 95% CI: 1.21-2.80, P = 0.004) and above the cardiac silhouette (HR: 2.22, 95% CI: 1.43-3.46, P = 0.0004)), larger amount of pleural fluid drained (HR: 1.06, 95% CI: 1.04-1.07, P < 0.0001) and higher pleural fluid LDH (HR: 1.008, 95% CI: 1.004-1.011, P < 0.0001) were associated with increased hazard of recurrence. Negative cytology (HR: 0.52, 95% CI: 0.43-0.64, P < 0.0001) was associated with decreased hazard of recurrence. The model had low prediction accuracy.
CONCLUSION: Pleural effusion size, amount of pleural fluid drained, LDH and pleural fluid cytology were found to be risk factors for recurrence.
© 2018 Asian Pacific Society of Respirology.

Entities:  

Keywords:  effusion recurrence; malignant pleural effusion; pleural effusion; thoracentesis

Mesh:

Substances:

Year:  2018        PMID: 29966171      PMCID: PMC7315912          DOI: 10.1111/resp.13362

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  7 in total

1.  Management of malignant pleural effusions.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-11       Impact factor: 21.405

2.  A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions.

Authors:  J B Putnam; R W Light; R M Rodriguez; R Ponn; J Olak; J S Pollak; R B Lee; D K Payne; G Graeber; K L Kovitz
Journal:  Cancer       Date:  1999-11-15       Impact factor: 6.860

3.  Management of Malignant Pleural Effusion: A Cost-Utility Analysis.

Authors:  Majid Shafiq; Kevin D Frick; Hans Lee; Lonny Yarmus; David J Feller-Kopman
Journal:  J Bronchology Interv Pulmonol       Date:  2015-07

4.  Outpatient management of malignant pleural effusions with small-bore, tunneled pleural catheters.

Authors:  Ali I Musani; Andrew R Haas; Luis Seijo; Mary Wilby; Daniel H Sterman
Journal:  Respiration       Date:  2004 Nov-Dec       Impact factor: 3.580

5.  Competing risk regression models for epidemiologic data.

Authors:  Bryan Lau; Stephen R Cole; Stephen J Gange
Journal:  Am J Epidemiol       Date:  2009-06-03       Impact factor: 4.897

6.  Comparison of modified Borg scale and visual analog scale dyspnea scores in predicting re-intervention after drainage of malignant pleural effusion.

Authors:  Rogier C Boshuizen; Andrew D Vincent; Michel M van den Heuvel
Journal:  Support Care Cancer       Date:  2013-07-11       Impact factor: 3.603

7.  Introduction to the Analysis of Survival Data in the Presence of Competing Risks.

Authors:  Peter C Austin; Douglas S Lee; Jason P Fine
Journal:  Circulation       Date:  2016-02-09       Impact factor: 29.690

  7 in total
  3 in total

1.  Breast and Lung Effusion Survival Score Models: Improving Survival Prediction in Patients With Malignant Pleural Effusion and Metastasis.

Authors:  Sofia Molina; Gabriela Martinez-Zayas; Paula V Sainz; Cheuk H Leung; Liang Li; Horiana B Grosu; Roberto Adachi; David E Ost
Journal:  Chest       Date:  2021-05-11       Impact factor: 10.262

Review 2.  Diagnosis and Management of Malignant Pleural Effusion: A Decade in Review.

Authors:  Blake Jacobs; Ghias Sheikh; Houssein A Youness; Jean I Keddissi; Tony Abdo
Journal:  Diagnostics (Basel)       Date:  2022-04-18

3.  Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations.

Authors:  Audra J Schwalk; David E Ost; Sahara N Saltijeral; Henriette De La Garza; Roberto F Casal; Carlos A Jimenez; Georgie A Eapen; Jeff Lewis; Waree Rinsurongkawong; Vadeerat Rinsurongkawong; Jack Lee; Yasir Elamin; Jianjun Zhang; Jack A Roth; Stephen Swisher; John V Heymach; Horiana B Grosu
Journal:  Chest       Date:  2020-11-17       Impact factor: 9.410

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.